Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer's disease or dementia: A case control study

European Neurology

Volumn 65, Issue 5, 2011, Pages 270-278

  Smach, Mohamed Ali ^a   Jacob, Nelly ^c   Golmard, Jean Louis ^c   Charfeddine, Bassem ^a   Lammouchi, Turkia ^b   Ben Othman, Leila ^a   Dridi, Hedi ^a   Bennamou, Soufien ^b   Limem, Khalifa ^a  

^a UNIVERSITY OF SOUSSE   (Tunisia)

^b SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Dementia; Folate; Homocysteine

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FOLIC ACID; HOMOCYSTEINE; TAU PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; DEMENTIA; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUNISIA;

EID: 79953727039     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000326301     Document Type: Article

References (44)

1. Ferri CP, Prince M, Brayne C, Brodaly H, Fratiglioni L, Ganguli M, et al: Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366: 2112-2117. (Pubitemid 41797645)
2. Blennow K, de Léon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006; 368: 387-403. (Pubitemid 44108123)
3. McKann G, Drachman DA, Folstein M, Katzman R, Price DL, Stadlan EM: Clinical diagnosis of Alzheimer's disease - report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task force on Alzheimer's disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
4. Glenner GG, Wong CW: Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-890. (Pubitemid 14104991)
5. Brion J, Passareiro E, Nunez J, Flament-Durand J: Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer. Arch Biol 1985; 95: 229-235. (Pubitemid 15000733)
6. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al: Evaluation of CSF-α and CSF-Aα 42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58: 373-379. (Pubitemid 32217453)
7. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al: Value of CSFα-amyloid-42 and tau as predictors of Alzheimer's disease in mild cognitive impairment. Mol Psychiatry 2004; 9: 705-710. (Pubitemid 38932175)
8. Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Canterero S, Cemillan C, et al: Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 2003; 60: 1218-1222. (Pubitemid 37099626)
9. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006; 5: 228-234. (Pubitemid 43238346)
10. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al: Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDSADRDA criteria. Lancet Neurol 2007; 6: 734-746. (Pubitemid 47058377)
11. Selkoe DJ: Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by cerebral accumulation and cytotoxicity of amyloidα-protein. Ann N Y Acad Sci 2000; 924: 17-25. (Pubitemid 32050177)
12. Rubenstein E: Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the age. Lancet 1998; 351: 283-285. (Pubitemid 28043962)
13. Corder EH, Saunders AM, Strittmatter WJ, Schechel DE, Gaskelle PC, Small GW, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in lateonset families. Science 1993; 261: 921-923. (Pubitemid 23275809)
14. Cavalieri M, Enzinger C, Petrovic K, Fuerst AP, Homayoon N, Schmidt H, et al: Vascular dementia and Alzheimer's disease - are we in a dead-end road? Neurodegener Dis 2010; 7: 122-126.
15. Dickstein DL, Walsh J, Brautigam H, Stocklon SD Jr, Gandy S, Hof PR: Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 2010; 77: 82-102.
16. Bowman GL, Quinn JF: Alzheimer's disease and the blood-brain barrier: Past, present and future. Aging Health 2008; 4: 47-55.
17. Weir DG, Scott JM: Brain function in the elderly: Role of vitamin B 12 and folate. Br Med Bull 1999; 55: 669-682.
18. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM: Folate, vitamin B 12 , and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-1455. (Pubitemid 28525506)
19. Ramos MI, Allen LH, Mungas DM, Jagust WJ, Haan MN, Green R, Miller JW: Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2005; 82: 1346-1352. (Pubitemid 43779735)
20. De Lau LM, Refsum H, Smith AD, Johnston C, Breteler MM: Plasma folate concentration and cognitive performance: Rotterdam Scan Study. Am J Clin Nutr 2007; 86: 728-734. (Pubitemid 47435841)
21. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483. (Pubitemid 34441738)
22. Sérot JM, Christmann D, Dubost T, Béné MC, Faure GC: CSF-folate levels are decreased in late-onset AD patients. J Neural Transm 2001; 108: 93-99. (Pubitemid 32692616)
23. Mulder C, Schoonenboom NS, Jansen EEW, Verhoeven NM, van Kamp GJ, Jakobs C, et al: The transmethylation cycle in the brain of Alzheimer patients. Neurosci Lett 2005; 386: 69-71. (Pubitemid 41058933)
24. Hagnelius NO, Wahlund LO, Nilsson TK: CSF/serum folate gradient: Physiology and determinants with special reference to dementia. Dement Geriatr Cogn Disord 2008; 25: 516-523. (Pubitemid 351957414)
25. Popp J, Lewczuk P, Linnebank M, Cvetanovska G, Smulders Y, Kölsch H, et al: Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis 2009; 18: 819-828.
26. Sérot JM, Barbé F, Arning E, Bottiglieri T, Franck P, Montagne P, Nicolas JP: Homocysteine and methylmalonic acid concentrations in cerebrospinal fluid: Relation with age and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1585-1587. (Pubitemid 41531713)
27. Isobe C, Murata T, Sato C, Terayama Y: Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 2005; 77: 1836-1843. (Pubitemid 41058987)
28. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
29. Bellaj T: Dysfonctionnement de la mémoire de travail dans la maladie d'Alzheimer; thesis, Faculté des Sciences Humaines et Sociales de Tunis, 1999.
30. Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR: Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: Findings from the Nun study. Am J Clin Nutr 2000; 71: 993-998. (Pubitemid 30176584)
31. Kim SR, Choi SH, Ha CK, Park SG, Pyun HW, Yoon DH: Plasma total homocysteine levels are not associated with medial temporal lobe atrophy, but with white matter changes in Alzheimer's disease. J Clin Neurol 2009; 5: 85-90.
32. Selley ML, Close DR, Stern SE: The effect of increased concentration of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002; 23: 383-388. (Pubitemid 34312021)
33. Linnebank M, Popp J, Smulders Y, Smith D, Semmler A, Farkas M, et al: S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. Neurodegener Dis 2010; 7: 373-378.
34. Spector R: Nutrient transport systems in brain: 40 years of progress. J Neurochem 2009; 111: 315-320.
35. Blom HJ, Wevers RA, Verrips A, TePoele- Pothoff MT, Trijbels JM: Cerebrospinal homocysteine and the cobalamin status of the brain. J Inherit Metab Dis 1993; 16: 517-519. (Pubitemid 23206841)
36. Obeid R, Kostopoulos P, Knapp JP, Kasoha M, Becker G, Fasbender K, Hermann W: Biomarkers of folate and vitamin B 12 are related in blood and cerebrospinal fluid. Clin Chem 2007; 53: 326-333. (Pubitemid 46338278)
37. Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becher G, Fasbender K, Hermann W: Folate and methylation status in relation to phosphorylated tau protein (181p) andα- amyloid (1-42) in cerebrospinal fluid. Clin Chem 2007; 53: 1129-1136. (Pubitemid 46867531)
38. Bottiglieri T, Reynolds EH, Laundy M: Folate in CSF and age. J Neurol Neurosurg Psychiatry 2000; 69; 562-567.
39. Ormazabal A, Garcia-Cazorla A, Pérez-Dueñas B, Gonzalez V, Fernandez-Álvarez E, Pineda M, et al: Determination of 5-methyltetrahydrofolate in cerebrospinal fluid of paediatric patients: Reference values for a paediatric population. Clin Chim Acta 2006; 371: 159-162. (Pubitemid 44177581)
40. Stabler SP, Allen RH, Barrett RE, Savage DG, Lindenbaum J: Cerebrospinal fluid methylmalonic acid levels in normal subjects and patients with cobalamin deficiency. Neurology 1991; 41: 1627-1632.
41. Hyland K, Bottiglieri T: Measurement of total plasma and cerebrospinal fluid homocysteine by fluorescence following high-performance liquid chromatography and precolumn derivatization with o -phtaldialdehyde. J Chromatogr 1992; 579: 55-62.
42. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PA, Weiner MW, et al: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
43. Alexopoulos P, Günther F, Popp J, Jessen F, Peters O, Wolf S, et al: Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia. J Am Geriatr Soc 2009; 57: 737-739.
44. Malouf R, Grimley Evans J: Folic acid with or without vitamin B 12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008; 4:CD004514